Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Sanofi

Clinicaltrial registered22 Oct 2026

Sanofi

22 Oct 2026: Trial registered · Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
22 Oct 2026
Title
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
Conditions
Immunization, Healthy Volunteers, COVID-19 Immunization, Influenza Immunization
Phase
Phase 3
Study Type
Interventional
Status
Recruiting
Countries
Poland
Country
Poland
Reference
NCT07890454
Location
Poland
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Sanofi

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Sanofi in our registers.

More from Poland

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.